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Abstract Tau protein, the major component of the aberrant 
structures termed paired helical filaments (PHFs) present in the 
brain of Alzbeimer's disease patients, is pathologically phos- 
phorylated in sites in and around the tubulin-binding sites. A 
single protein kinase, glycogen synthase kinase 3 (GSK 3), is able 
to phosphorylate tau at the flanking regions and, additionally, at 
the tubulin-binding motifs if heparin or tubulin is present. Serines- 
262 and -324 have been found to be modified at the tubulin- 
binding region of tau protein by GSK 3 in the presence of heparin 
or tubulin. 
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I. Introduction 
Microtubule-associated protein tau [1] plays a role in the 
stabilisation of polymerised microtubules [2-4]. This role is 
abolished in a neuropathological situation, Alzheimer's disease 
(AD), in which the capacity for microtubule binding of tau 
protein decreases [5,6]. Furthermore, tau protein in AD, in a 
modified form, is the main component of the aberrant struc- 
tures termed as paired helical filaments (PHFs) present in the 
brain of the patients [7-12]. 
Several post-translational modifications have been described 
for tau protein [11-14]. One of these, phosphorylation, has been 
suggested to precede PHF formation [15]. Tau phosphorylation 
has been extensively studied in vitro and in PHF-associated tau 
[16]. There are three main types of proline-directed protein 
kinases which could modify tau in vitro. GSK 3 (glycogen 
synthase-kinase 3) [17,18], cdc-2 like kinases [19 21], and MAP 
kinases [22]. Proteins related to the first two types that have 
been found to be associated to microtubules, howing a capac- 
ity to phosphorylate tau, are termed as tau kinases I and II 
[18,23]. The modification oftau by these kinases does not signif- 
icantly decrease the binding of tau to microtubules, a feature 
observed for AD tau [5]. However, Biernat et al. [6] have de- 
scribed a modification in Ser-262, which could dramatically 
decrease the interaction of tau for microtubules. Additionally, 
Correas et al. [24] described a related serine, present in the 
second tubulin- binding domain of tau, phosphorylated by pro- 
tein kinase C. Such phosphorylation also results in a decrease 
in the interaction of the protein with microtubules. 
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Abbreviations. GSK 3, glycogen synthase kinase 3: MAE microtubule 
associated protein. 
GSK 3 consists of two related proteins, GSK 3c~ and GSK 
3fl [24] first described as a modulator of glycogen metabolism, 
phosphorylating glycogen synthase and mediating insulin regu- 
lation of glycogen synthesis [26]. Several studies have described 
that either GSK 3~ or GSK 3fl are able to modify tau [17,18,27- 
30]. Moreover, it has been shown by co-transfection studies 
that GSK 3fl could modify tau in cultured cells at some of the 
residues that are also modified in AD-tau [31]. 
2. Materials and methods 
2.1. Materials 
The peptides KVTSKCGSLGNIHHKPGGG, and KVTAKCGS- 
LGNIHHKPGGG, were purchased from Med Probe A.S. (Oslo, Nor- 
way). The peptide TAEEEEDFGEEAEEEA corresponding to tubulin 
fl isoform (mouse fls) [32] was synthesized on an automatic solid phase 
peptide synthesizer (type 430A, Applied Biosystems) and purified by 
reverse-phase HPLC on a NovoPak C 18 column. Heparin was obtained 
from Lab. Farm. Rovi (Barcelona, Spain), S.A. T4 polynucleotide 
kinase, Klenow enzyme, T4 DNA ligase and restriction enzymes were 
purchased from Boehringer. T7 DNA polymerase was from Pharmacia. 
Ampli Taq polymerase was from Perkin Elmer-Cetus. Synthetic ol- 
igonucleotides were from Isogen Bioscience (Amsterdam). 
2.2. C~mstruetion j expression plasmids and pur(fieation qfrecombinant 
tau isoforms and fragments from E coli 
Human tau cDNA clones (htau 23 and htau 40) were kindly supplied 
by Dr. M. Goedert (M.R.C. Cambridge, UK). Additionally, several tau 
fragments were cloned into the expression vector pRKI72 [33]. To 
obtain plasmids pRKT3RC, pRKT2R, pRKT3R and pRKT4R for 
inducible xpression in E. coli, mutagenesis was carried out using the 
polymerase chain reaction (PCR). Oligonucleotides A5 (GCGGATC- 
CATATGCCAGACCTG), which include the initiation codon as well 
as BamHI and Ndel sites for a proper cloning into the vector, was used 
as 5' primer. Oligonucleotide A7 (GCGAATTCTTACTCGCGGA- 
AGG), A8 (GCGAATTCTCACAAACCCTGCTTGG) and A10 
(CCGGAATTCTAAAGCTTCTCAGATTTTAC), which include a 
stop codon and an EeoRI site downstream, were used as 3' primers. The 
fragment generated by PCR amplification on pSGT3RC using primers 
A5 and A8 (503 bp) was digested with NdeI and EeoRI and ligated into 
pRK172 and also digested with Ndel and EeoRI to obtain pRKT3RC. 
Primers A5 and A7 were used on pSGT3R and pSGT4R [34] and the 
amplified fragments (321 bp and 384 bp, respectively) were digested 
with NdeI and EcoR[ and ligated into Ndel- and EeoRI-digested 
pRK172 to obtain pRKT3R and pRKT4R, respectively. Primers A5 
and Al0 were used to amplify a 205 bp fragment that was used, after 
digestion with NdeI and EeoRI and ligation into pRK172 also digested 
with NdeI and EcoRI, to obtain pRK2R. All plasmids were analyzed 
by restriction analysis to test for the proper orientation and correct size 
of the inserts. Finally, when cDNAs obtained by PCR amplification 
were tested by sequencing, no changes regarding the template sequences 
were observed. Recombinant tau protein was purified [34], including a
boiling step to prevent possible contamination f endogenous enzy- 
matic activities. 
2.3. Protein preparation 
GSK 3 was purified from bovine brain essentially as described by 
Woodgett [25], by chromatography on DEAE-cellulose, phosphocellu- 
lose and heparin-Sepharose. In some cases the further step in column 
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filtration on Sephacryl was replaced by a mono S-2 chromatography 
on a FPLC system (Pharmacia). A specific activity of 0.15/2mol of 
phosphate incorporated/min/mg of substrate (recombinant tau protein) 
was calculated for the GSK 3 preparation. 
Tubulin depleted of MAPs was isolated from bovine brain by 
phosphocellulose chromatography [1]. Tubulin lacking its C-terminal 
region was obtained by subtilisin digestion [35]. The proteins were 
characterized by gel electrophoresis, and in the case of labelled proteins, 
by autoradiography as previously described [28]. 
2.4. Enzymatic assays 
GSK 3 assays were carried out as described by Stambolic and 
Woodgett [36] in a buffer containing 50/2M [7-32p]ATP, 25 mM Tris 
pH 7.5, 1 mM DTT, 10 mM MgClz and 1 mM EGTA. 
The interaction of tau fragments, containing three tubulin-binding 
motifs in phosphorylated or unmodified form, with microtubules was 
carried out as described by Medina et al. [34]. 
2.5. Protein sequencing 
Tryptic peptides of tau protein were fractionated by HPLC, using a 
NovoPack column, in the conditions described by Nieto et al• [5], and 
these peptides containing phosphate label were blotted on immobilon 
paper (Millipore) and sequenced with an Applied-Biosystem gas phase 
sequenator (model 470A) equipped with an on-line phenylthiohydan- 
toin amino acid analyser (model 120A). 
3. Results 
3.1. Recombinant tau is phosphorylated by GSK 3 
Fig. 1 shows that the whole molecule of tau (isoform tau 31) 
is a substrate for GSK 3. It has been indicated that heparin 
could increase the phosphorylation f tau by kinases like PKA 
[37] and also by GSK 3 [18]. Thus, we have tested the incorpo- 
ration of phosphate in tau, by GSK 3, after adding heparin. In 
the presence of heparin, an 8-fold increase was observed in the 
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Fig. 1. Determination f phosphate incorporated into tau 31 by GSK 3. 
10/21 aliquots of purified tau 31 (0.35 mg/ml) were incubated with GSK 
3 at different concentrations of 32p-labelled ATP for 20 rain at 37°C, 
in the absence (o) or in the presence of 0.1 mg/ml of heparin ($). After 
incubation, each aliquot was run on SDS-gel electrophoresis, and the 
region containing tau protein was excised from the gel. The radio- 
activity associated with tau was measured by Cerenkov radiation, taken 
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Fig. 2. Effect of heparin on the phosphorylation f tau fragments 3RC 
and 3R. The enzyme was assayed in the presence of the indicated 
increasing heparin concentrations using tau 3RC at 0.2 mg/ml (A) or 
tau 3R at the same concentration (B). Phosphate incorporation was 
measured as indicated in Fig. 1. In ordinate isindicated the comparison 
of the incorporation ofphosphate into protein determined by gel elec- 
trophoresis, and autoradiography. 
increase was found to be dependent on both protein and hepa- 
rin concentration. 
3.2. Localization of tau residues modified by GSK 3 
Tau fragment lacking the amino terminal region (tau 3RC) 
is also a suitable substrate for GSK 3 (Fig. 2). Additionally, the 
modification oftau 3RC fragment also increases in the presence 
of heparin (Fig. 2). Since the tau fragment ested (3RC) con- 
tains both the tubulin-binding and carboxy-terminal regions, 
we tested whether one or both of these regions could be mod- 
ified by GSK 3. Fig. 2 indicates that both of them are 
phosphorylated by GSK 3, since not only fragment 3RC, but 
also fragment 3R (containing the three tubulin-binding mo- 
tifs), could be phosphorylated. However, the presence of hepa- 
rin appears to be essential for the modification of 3R, since no 
phosphorylation was detected in its absence. Since different, 
but related, tubulin binding motifs can be found in tau 
isoforms, it is possible that GSK 3 could modify serine residues 
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Fig. 3. Phosphorylation f tubulin binding motifs present in tau protein 
by GSK 3 in the presence of heparin. The enzyme was assayed in the 
presence of 0.1 mg/ml heparin and the different tau fragments contain- 
ing four, three, two and a part of a single tubulin-binding repeat. The 
amount of radioactivity incorporated into the different tau fragments 
was determined as indicated in legend of Fig. 1. 
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Fig. 4. GSK 3 phosphorylation sites on tau tubulin binding domain of 
tau protein. Tau 2R was phosphorylated with GSK 3 in the presence 
of heparin and 32P-ATE Tryptic peptides of phosphorylated tau were 
fractionated by HPLC and the peptides containing phosphate label 
were blotted onto Immobilon paper and sequenced as described under 
section 2. Peptide sequences obtained are indicated as inserts. 
ments containing four, three, two and a part of a single tubulin- 
binding repeat were incubated in the presence of GSK 3 and 
the relative phosphate incorporation was measured. Fig. 3 indi- 
cates that the incorporation of phosphate into the different tau 
fragments is related to the number of repeats present in each 
fragment. The result suggests that serines present in related 
sequences of the motifs could all be phosphorylated. These 
serines could be related to the presence of residue 324 at the 
third repeat (of a four-repeat tau protein), since a similar value 
was obtained when the incorporation ofphosphate into peptide 
IR (KVTSKCGSLGNIHHKPGGG) was compared to peptide 
(KVTAKCGSLGNIHHKPGGG),  after incubation with GSK 
3 and heparin. 
3.3. Serine-262 is modified by GSK 3 in the presence of heparin 
In order to identify the residues modified by GSK 3, the tau 
fragment containing the first two repeats was incubated with 
the kinase in the presence of heparin and afterwards prote- 
olyzed with trypsin. Those tryptic fragments containing phos- 
phate label were sequenced. Fig. 4 indicates the chromatogra- 
phy pattern of tryptic peptide fractionation and the sequence 
of those peptides howing a higher phosphorylation level. In 
one case a phosphopeptide contains erine-262, present in the 
first tubulin-binding motif and in the other case the 
phosphopeptide contains erine-324, which is present in a re- 
lated sequence to that of serine-262, in the third tubulin-binding 
motif of tau protein. 
3.4. The phosphorylation of tau binding motifs reduces the 
interaction of the modified protein for microtubules 
To test whether the phosphorylation f tubulin-binding mo- 
tifs of the tau protein by GSK 3, in the presence of heparin, 
modifies the interaction of the protein for microtubules, tau 
fragment 3R, containing only the tubulin-binding motifs that 
can interact with microtubules [38], was incubated with GSK 
3 plus heparin. After incubation, heparin was removed by 
DEAE-chromatography, and both modified and unmodified 
proteins were incubated in the presence of increasing concen- 
trations of assembled microtubules tostudy their binding affin- 
ities for them. A three fold increase in the Kd (17 pM) of the 
modified protein compared to that of the unmodified tau frag- 
ment (Kd, 6/.tM) was observed. 
3.5. Tubulin-b&ding motifs present in tau protein are 
phosphorylated by GSK 3 in the presence of tubulin 
The carboxy terminal region of tubulin contains a cluster of 
acidic residues involved in the binding of microtubule-associ- 
ated proteins [35,39], which could be considered as a polyanion. 
GSK 3 was incubated with tau fragment 3R in the presence of 
increasing concentrations of heparin or tubulin in order to test 
whether tubulin could, through the presence of the negative 
charges, facilitate the phosphorylation f tau by GSK 3, at its 
tubulin-binding repeats. Fig. 5 shows that both, heparin and 
tubulin, act as promoters of GSK 3 phosphorylation, but not 
tubulin lacking its acidic carboxy terminal region. However, a 
peptide containing the last residues of a tubulin fl isoform 
(mouse 135 [32]) is able to favour the phosphorylation f tau by 
GSK 3. 
4. Discussion 
In the present work it has been shown that tau protein in the 
presence of heparin (or tubulin) could be phosphorylated at
serine-262, a residue that is phosphorylated in vivo in the brain 
of AD patients [12]. Such phosphorylation also results in a 
decrease in the interaction of tau protein for microtubules [6]. 
Despite multiple phosphorylation through the whole tau mole- 
cule by MAP kinase or GSK 3 [17,18,22,27-30], PHF cores are 
formed by the tubulin binding domains of tau protein, lacking 
the flanking regions [8]. Serine-262 is located within the first 
tubulin binding domain, thus becoming phosphorylation on 
this residue more interesting, since it is present in truncated tau 
from PHF cores [40]. 
In relation to the phosphorylation at the tubulin-binding 
motifs of tau, it has been suggested that some kinases could 
phosphorylate at serine-262 [6] or at serine-324 [24,41]. In the 
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Fig. 5. Phosphorylation f tubulin-binding motifs present in tau protein 
by GSK 3 was stimulated by heparin and tubulin. The enzyme was 
assayed in the presence of increasing amounts of heparin (circles), 
tubulin (squares) and subtilisin-digested tubulin lacking the terminal 
region (triangles) or the peptide corresponding tothe C-terminal region 
of mouse fls isoform (filled triangles) at the indicated concentrations, 
using tau 3R at 0.2 mg/ml. Phosphate incorporation was measured as 
indicated in the legend of Fig. 2. 
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present work it has been shown that GSK 3 could also modify 
the previous erines. Thus, a single kinase GSK 3 could phos- 
phorylate at both tubulin-binding and flanking regions. 
The action of heparin on GSK 3 activity on tau appears to 
be similar to that of tubulin. It could be due to the anionic 
character of heparin and the C-terminal region of tubulin sub- 
units, a region involved in the binding of microtubule-associ- 
ated proteins [35], including tau protein [39]. Thus, a tubulin- 
GSK 3-tau complex could be formed, resulting in the modifica- 
tion of tau, at the serine-262, of the tubulin-binding motifs. 
As indicated in this work and previous works [6], the result 
of this modification could be a decrease in the interaction of 
the tau protein with microtubules. As a consequence of the 
lower microtubule association of tau, and the reported observa- 
tion indicating that modified protein could have a slower turn- 
over [42], the formation of tau aggregates, even that of PHF's, 
could be favoured. 
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